All In Biotech

Drug Trial Radar · NCT04379271

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19

Last checked: Nov 19, 2026Latest source record: Nov 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

234

Actual

Start

Jun 11, 2020

Primary completion

Jan 12, 2021

Study completion Feb 23, 2021

Sponsor

Lead sponsor
Immunic AGIndustry
Sponsor type
Industry
Collaborators
FGK Clinical Research GmbH
First posted
May 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

At present there is no approved drug treatment for Covid-19. In this study we plan to investigate if an experimental drug called IMU-838 (vidofludimus calcium) can improve your symptoms, prevent worsening that would initiate further treatments such as ventilation, and can lower your virus number if given in addition to your doctor's choice of standard therapy. We will also test if IMU-838 has any side effects and measure the level of IMU 838 in your blood. Experimental drug means that it is not yet authorized for marketing in your country. To date approximately 600 individuals have received IMU-838 (or a drug similar to IMU-838 that contains the same active substance as IMU-838) in research studies.

Conditions

  • COVID-19

Interventions

  • IMU-838Drug

    Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable). If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube.

  • PlaceboOther

    Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Without Any Need for INV Until EoSTime frame: Throughout the Study (Day 0 to Day 28)

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Military Medical Academy, Clinic of Infectious Diseases

    Sofia, Bulgaria

  • UMHATEM N.I.Pirogov, Clinic of internal diseases

    Sofia, Bulgaria

  • University Hospital Frankfurt, Infectious Diseases

    Frankfurt, Germany

  • Clinic of the Hannover Medical School, Pneumology Clinic

    Hanover, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.